Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.

Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Lee SD, Kim WS, Kim DS, Shim TS.

Respir Med. 2013 Nov;107(11):1797-802. doi: 10.1016/j.rmed.2013.08.011. Epub 2013 Aug 28.

2.

Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.

Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, Kang ES, Koh WJ.

Clin Rheumatol. 2011 Dec;30(12):1535-41. doi: 10.1007/s10067-011-1771-9. Epub 2011 May 10.

PMID:
21556777
3.

Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.

Kim HC, Jo KW, Jung YJ, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Shim TS.

Scand J Infect Dis. 2014 Nov;46(11):763-9. doi: 10.3109/00365548.2014.938691. Epub 2014 Sep 8.

PMID:
25195652
4.

The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment.

Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Lee KH, Lee SD, Kim WS, Kim DS, Shim TS.

Int J Tuberc Lung Dis. 2014 Apr;18(4):428-34. doi: 10.5588/ijtld.13.0644.

PMID:
24670697
5.

Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.

Park JH, Seo GY, Lee JS, Kim TH, Yoo DH.

J Rheumatol. 2009 Oct;36(10):2158-63. doi: 10.3899/jrheum.090150. Epub 2009 Sep 1.

PMID:
19723901
6.

Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.

Kwon M, Sung M, Kwon YJ, Song YG, Lee SW, Park MC, Park YB, Lee SK, Song JJ.

J Clin Rheumatol. 2014 Mar;20(2):68-73. doi: 10.1097/RHU.0000000000000074.

PMID:
24561408
7.

Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.

Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH.

J Korean Med Sci. 2014 Jan;29(1):38-42. doi: 10.3346/jkms.2014.29.1.38. Epub 2013 Dec 26. Erratum in: J Korean Med Sci. 2014 Mar;29(3):460.

8.

Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.

Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA.

Lung. 2013 Oct;191(5):565-71. doi: 10.1007/s00408-013-9481-5. Epub 2013 Jun 1.

PMID:
23728990
9.

Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.

Papay P, Primas C, Eser A, Novacek G, Winkler S, Frantal S, Angelberger S, Mikulits A, Dejaco C, Kazemi-Shirazi L, Vogelsang H, Reinisch W.

Aliment Pharmacol Ther. 2012 Nov;36(9):858-65.

10.

Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.

Costantino F, de Carvalho Bittencourt M, Rat AC, Loeuille D, Dintinger H, Béné MC, Faure G, Chary-Valckenaere I.

J Rheumatol. 2013 Dec;40(12):1986-93. doi: 10.3899/jrheum.130303. Epub 2013 Oct 1.

PMID:
24085550
11.
12.

Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.

Kim ES, Song GA, Cho KB, Park KS, Kim KO, Jang BI, Kim EY, Jeon SW, Lee HS, Yang CH, Lee YK, Lee DW, Kim SK, Kim TO, Lee J, Kim HW, Jee SR, Park SJ, Kim HJ.

World J Gastroenterol. 2015 Mar 21;21(11):3308-16. doi: 10.3748/wjg.v21.i11.3308.

13.

Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.

Jung SM, Ju JH, Park MS, Kwok SK, Park KS, Kim HY, Yim HW, Park SH.

Int J Rheum Dis. 2015 Mar;18(3):323-30. doi: 10.1111/1756-185X.12530. Epub 2015 Jan 3.

PMID:
25557144
14.

Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy.

Yoo IK, Choung RS, Hyun JJ, Kim SY, Jung SW, Koo JS, Lee SW, Choi JH, Kim H, Lee HS, Keum B, Kim ES, Jeen YT.

Yonsei Med J. 2014 Mar;55(2):442-8. doi: 10.3349/ymj.2014.55.2.442.

15.

Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.

Li CR, Mao QX, Chen M, Jia WX, Yao X, Feng SY, Jia H, Gong JQ, Yang XY.

Drug Des Devel Ther. 2015 Oct 12;9:5591-4. doi: 10.2147/DDDT.S87260. eCollection 2015.

16.

QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.

Lee H, Park HY, Jeon K, Jeong BH, Hwang JW, Lee J, Cha HS, Koh EM, Kang ES, Koh WJ.

PLoS One. 2015 Mar 6;10(3):e0119260. doi: 10.1371/journal.pone.0119260. eCollection 2015.

17.

[The clinical application of quantiferon TB-2G: its usefulness and limitations].

Sato S, Nagai H.

Kekkaku. 2011 Feb;86(2):101-12. Japanese.

PMID:
21404654
18.

Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.

Kurt OK, Kurt B, Talay F, Tug T, Soy M, Bes C, Hayran M.

Wien Klin Wochenschr. 2013 Oct;125(19-20):616-20. doi: 10.1007/s00508-013-0417-0. Epub 2013 Sep 6.

PMID:
24061693
19.

Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P.

Ann Rheum Dis. 2012 Nov;71(11):1783-90. doi: 10.1136/annrheumdis-2011-200408. Epub 2012 Jan 17.

PMID:
22258485
20.

How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.

Bermejo F, Algaba A, Chaparro M, Taxonera C, Garrido E, García-Arata I, Guerra I, Gisbert JP, Olivares D, de-la-Poza G, López-Sanromán A.

Dig Liver Dis. 2013 Sep;45(9):733-7. doi: 10.1016/j.dld.2013.03.005. Epub 2013 Apr 12.

PMID:
23587496

Supplemental Content

Support Center